Update in Interstitial Lung Disease 2019

• Published in: American journal of respiratory and critical care medicine 2020-08, Vol.202 (4), p.500-507
• Main Authors: Montesi, Sydney B, Fisher, Jolene H, Martinez, Fernando J, Selman, Moisés, Pardo, Annie, Johannson, Kerri A
• Format: Article
• Language: English
• Subjects: Chronic obstructive pulmonary disease; Humans; Lung diseases; Lung Diseases, Interstitial - diagnosis; Lung Diseases, Interstitial - etiology; Lung Diseases, Interstitial - therapy; Medical research; Medical treatment; Prognosis; Pulmonary fibrosis; Pulmonary, Sleep, and Critical Care Update; Scleroderma
• ISSN: 1073-449X; 1535-4970
• DOI: 10.1164/rccm.202002-0360UP

The year 2019 brought advances in our understanding of pulmonary fibrosis, including disease burden, elucidation of pathogenic drivers of fibrogenesis and potential therapeutic targets, identification of outcome predictors, application of molecular imaging to fibrosis, and demonstration of efficacy of antifibrotic therapy in progressive non-idiopathic pulmonary fibrosis inierstitial lung diseases (ILDs). Here, Montesi et al review critical research in the field of pulmonary fibrosis published over the past year in the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology, and AnnalsATS and highlight notable findings published in other major journals. They acknowledge that not every major advancement could be captured in this update. The impact of ILD in patients with systemic sclerosis (SSc) was assessed in a nationwide cohort of 815 patients in Norway. Of the 650 patients with SSc with a baseline high resolution computed tomography exam, half had evidence of ILD.